Investors never know what to expect for Ceradyne
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Ceradyne with three of five analysts rating it hold. While analysts still rate the stock a hold, they are a little more optimistic about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $120.1 million in revenue this quarter. That would represent a decline of 20% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.36 per share. Estimates range from $0.25 to $0.45.
What our community says:
CAPS All-Stars are strongly supporting the stock, with 97.9% granting it an "outperform" rating. The greater community is in line with the All-Stars, as 97.3% give it a rating of "outperform." With just three posts in the past month, Fools have kept relatively quiet about Ceradyne despite their generally positive feelings towards the stock. Ceradyne has a bullish CAPS rating of five out of five stars that is about on par with Fool community assessment.
Ceradyne's profit has risen year-over-year by an average of more than threefold over the past five quarters.
For all our Ceradyne-specific analysis, including earnings and beyond, add Ceradyne to My Watchlist.
The Motley Fool owns shares of Ceradyne. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.